The U.S. Food and Drug Administration (FDA) recently informed customers that they should not purchase nor use Propell Platinum, a product that is marketed and sold for weight loss on its website, www.sztbeepollenpills.com, and select retail stores.
A laboratory analysis form the FDA has confirmed that the product has sibutramine, which is a controlled substance that was first taken off the market for safety concerns in October 2010.
Propell Platinum is a health threat to customers; sibutramine is proven to raise pulse rates and blood pressures in certain patients. This may cause a significant health risk for the consumers who have histories of congestive heart failure, coronary artery disease, stroke or arrhythmias.
In addition, sibutramine can harmfully and dangerously interact with other treatments and medications that people may be taking.
The analysis from the FDA laboratory also confirmed that the product has phenolphthalein, a chemical that is not included in any approved drug within the U.S. This active ingredient may increase patients' risk of developing cancer.
All health experts as well as patients are asked to report any side effects or adverse events that may be linked to Propell Platinum. They can report these concerns using the FDA’s MedWatch Safety Information and Adverse Event Reporting Program -- or by visiting the MedWatch Voluntary Reporting Form online, downloading it and faxing it to the FDA.